ESMO 2022 Conference Coverage

 

GU
06:54

ESMO 2022 Conference Coverage

ESMO 2022 on the JAVELIN Bladder 100 Trial: Avelumab 1L Maintenance for Advanced Urothelial Carcinoma - Results From Patients With ≥12 Months of Treatment

FEATURING Jeanny Aragon-Ching
  • 248 views
  • October 10, 2022
  • 3
05:10

ESMO 2022 Conference Coverage

ESMO 2022 on the Results From the PREVAIL Prospective Cohort Study: Prevalence of PD-L1 High Expression in Advanced Urothelial Carcinoma

FEATURING Petros Grivas
  • 148 views
  • September 27, 2022
09:42

ESMO 2022 Conference Coverage

ESMO 2022 on the Phase 1 Study of PRL-02, a Long-Acting IM Depot Injection of Abiraterone Decanoate in Patients With Prostate Cancer

FEATURING Jose Avitia
  • 43 views
  • September 27, 2022
05:53

ESMO 2022 Conference Coverage

ESMO 2022 Initial Results From the Phase 3 SPLASH Study: Efficacy and Safety of 177Lu-PNT2002 PSMA Therapy in mCRPC

FEATURING Aaron Hansen
  • 280 views
  • September 21, 2022
02:47

ESMO 2022 Conference Coverage

ESMO 2022 on the Phase 3 VISION Trial: Comparing 177Lu-PSMA-617 Treatment With a Change in Androgen Receptor Pathway Inhibitor in Taxane-Naïve Patients With mCRPC

FEATURING Andrew Armstrong
  • 182 views
  • September 21, 2022
05:47

ESMO 2022 Conference Coverage

ESMO 2022 on the Impact of TURBT and Intravesical BCG vs. Radical Cystectomy on Disease-Specific Survival of High-Risk NMIBC: A Meta-Analysis of Comparative Studies

FEATURING Philip Haddad
  • 136 views
  • September 20, 2022
04:35

ESMO 2022 Conference Coverage

ESMO 2022 on the 4-Factor Model to Predict Response and Survival Benefit With Durvalumab in Previously Treated Metastatic Urinary Tract Carcinoma

FEATURING Guru Sonpavde
  • 134 views
  • September 19, 2022
12:10

ESMO 2022 Conference Coverage

ESMO 2022: Key Bladder Cancer/Urothelial Carcinoma Presentations

FEATURING Guru Sonpavde
  • 810 views
  • September 16, 2022
  • 1